search
Back to results

Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Primary Purpose

Small Cell Lung Cancer

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
irinotecan
Sponsored by
Guangdong Association of Clinical Trials
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Small Cell Lung Cancer focused on measuring irinotecan, Small Cell Lung Cancer

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 to 65 years, male and female
  2. Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC )(except metastases only as pleural effusion)
  3. No prior chemotherapy
  4. Metastatic lesion had been treated more than 14 days by palliative radiation therapy or surgery
  5. With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need short diameter need more then 15mm, and the lesions can be accurately evaluated repeatedly measurable)
  6. Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1
  7. Expected survival ≥ 3months
  8. Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of

    • absolute neutrophil coun(ANC) ≥ 2.0 × 109 / L
    • blood platelet(PLT) ≥ 100 × 109 / L
    • Hb≥ 90g / L
    • conjugative bilirubin(CB)≤ upper limit of normal(ULN) × 1.5
    • Aspartate transaminase(AST )(glutamic oxalacetic transaminase,GOT): ≤ upper limit of normal(ULN )× 2.5
    • Alanine aminotransferase(ALT)(Glutamate Pyruvate Transaminase,GPT): ≤ ULN × 2.5
    • Serum creatinine: ≤ ULN or calculated creatinine clearance≥ 60 ml / min
    • (PT INR) ≤ ULN × 1.5
    • ECG: no abnormalities in need of treatment
  9. No pregnancy or no pregnancy demand at the end of the study within six months
  10. Must provide written informed consent.

Exclusion Criteria:

  1. Patient have platinum compounds allergy history
  2. Patient with active ulcer disease or chronic enteritis patients
  3. Primary lesion(s) has (have) been treated by Surgery or radiation
  4. Patient had received Immune drugs treatment for anti-lung cancer indications or anti-cancer Chinese traditional medicine treatment within two weeks
  5. Patients with interstitial pneumonia or pulmonary fibrosis
  6. Brain metastasis requiring treatment
  7. Patient with bronchus or bronchial stenosis or blockage and superior vena cava syndrome caused by serious invasion
  8. Patients with severe infections, severe abnormal secretion of (Anti Diuretic Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring treatment vena cava syndrome
  9. Severe cardiovascular disease: hypertension that medical treatment can not be controlled , unstable angina, myocardial infarction within the last June a history of congestive heart failure> 3 (NYHA) and severe arrhythmia

Sites / Locations

  • Jilin cancer hospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

irinotecan

Arm Description

irinotecan; 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2

Outcomes

Primary Outcome Measures

Limiting Toxicity (DLT )in the irinotecan

Secondary Outcome Measures

Maximum Tolerated Dose(MTD)in the irinotecan

Full Information

First Posted
June 16, 2014
Last Updated
February 2, 2021
Sponsor
Guangdong Association of Clinical Trials
search

1. Study Identification

Unique Protocol Identification Number
NCT02171325
Brief Title
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Official Title
A Phase Ⅱ Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 2014 (undefined)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
June 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Guangdong Association of Clinical Trials

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.
Detailed Description
To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Small Cell Lung Cancer
Keywords
irinotecan, Small Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
54 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
irinotecan
Arm Type
Experimental
Arm Description
irinotecan; 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Intervention Type
Drug
Intervention Name(s)
irinotecan
Intervention Description
60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Primary Outcome Measure Information:
Title
Limiting Toxicity (DLT )in the irinotecan
Time Frame
up to 18 weeks
Secondary Outcome Measure Information:
Title
Maximum Tolerated Dose(MTD)in the irinotecan
Time Frame
up to 18weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 to 65 years, male and female Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC )(except metastases only as pleural effusion) No prior chemotherapy Metastatic lesion had been treated more than 14 days by palliative radiation therapy or surgery With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need short diameter need more then 15mm, and the lesions can be accurately evaluated repeatedly measurable) Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1 Expected survival ≥ 3months Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of absolute neutrophil coun(ANC) ≥ 2.0 × 109 / L blood platelet(PLT) ≥ 100 × 109 / L Hb≥ 90g / L conjugative bilirubin(CB)≤ upper limit of normal(ULN) × 1.5 Aspartate transaminase(AST )(glutamic oxalacetic transaminase,GOT): ≤ upper limit of normal(ULN )× 2.5 Alanine aminotransferase(ALT)(Glutamate Pyruvate Transaminase,GPT): ≤ ULN × 2.5 Serum creatinine: ≤ ULN or calculated creatinine clearance≥ 60 ml / min (PT INR) ≤ ULN × 1.5 ECG: no abnormalities in need of treatment No pregnancy or no pregnancy demand at the end of the study within six months Must provide written informed consent. Exclusion Criteria: Patient have platinum compounds allergy history Patient with active ulcer disease or chronic enteritis patients Primary lesion(s) has (have) been treated by Surgery or radiation Patient had received Immune drugs treatment for anti-lung cancer indications or anti-cancer Chinese traditional medicine treatment within two weeks Patients with interstitial pneumonia or pulmonary fibrosis Brain metastasis requiring treatment Patient with bronchus or bronchial stenosis or blockage and superior vena cava syndrome caused by serious invasion Patients with severe infections, severe abnormal secretion of (Anti Diuretic Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring treatment vena cava syndrome Severe cardiovascular disease: hypertension that medical treatment can not be controlled , unstable angina, myocardial infarction within the last June a history of congestive heart failure> 3 (NYHA) and severe arrhythmia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
ying cheng, doctor
Phone
86-43185871902
Email
jl.cheng@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
qian liu, bachelor
Phone
86-43185873196
Email
xjy0202@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ying cheng, doctor
Organizational Affiliation
Jilin Provincial Tumor Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jilin cancer hospital
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ying cheng, doctor
Phone
86-43185871902
Email
jl.cheng@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

We'll reach out to this number within 24 hrs